Acta Med. 2013, 56: 9-13
https://doi.org/10.14712/18059694.2014.31
FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS
References
1. N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011; 183: 25–35.
<https://doi.org/10.1007/978-3-540-85772-3_2>
2. RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.
<https://doi.org/10.1038/leu.2008.291>
<PubMed>
3. B, Sheehe PR, Cuttner J, et al. Melphalan in multiple myeloma. Blood. 1967; 30: 74–83.
<https://doi.org/10.1182/blood.V30.1.74.74>
4. M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–7.
<https://doi.org/10.1056/NEJM199607113350204>
5. B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010; 28: 1209–14.
<https://doi.org/10.1200/JCO.2009.25.6081>
<PubMed>
6. JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114: 3139–46.
<https://doi.org/10.1182/blood-2009-03-201053>
7. BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36, 842–54.
<https://doi.org/10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U>
8. J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–23.
<https://doi.org/10.1046/j.1365-2141.1998.00930.x>
9. S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–63.
<https://doi.org/10.1182/blood.V91.3.756>
10. S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. Med Oncol 2010; 27 Suppl 1: S14–24.
<https://doi.org/10.1007/s12032-009-9370-1>
11. J, Rosiñol L, Sureda A, et al. Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–9.
<https://doi.org/10.1182/blood-2005-03-1301>
12. B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–64.
<https://doi.org/10.1111/j.1365-2141.2006.06271.x>
13. A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–7.
<https://doi.org/10.1182/blood-2004-02-0408>
14. M, van Rhee F, Anaissie E, et al. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 2008; 141: 433–44.
<https://doi.org/10.1111/j.1365-2141.2008.06982.x>
<PubMed>
15. M, Scudla V, Tothova E, et al. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. Clin Lymphoma Myeloma 2009; 9: 436–42.
<https://doi.org/10.3816/CLM.2009.n.086>
16. JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–84.
<https://doi.org/10.1182/blood-2006-07-038430>
17. SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011; 118: 4359–62.
<https://doi.org/10.1182/blood-2011-03-342089>
<PubMed>
18. JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009; 27: 5720–6.
<https://doi.org/10.1200/JCO.2008.21.1060>
19. B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375–82.
<https://doi.org/10.1182/blood-2008-07-167379>
<PubMed>
20. B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016–22.
<https://doi.org/10.1200/JCO.2010.32.7312>
